Response to Merz

Jon Merz raises two objections to our article on the ethics of behavioral influences in trial recruitment. In this response, we defend our article against these objections. We argue that Merz’s critique rests on a misunderstanding of our article, defend the daily life standard as a guardrail for lev...

Descripción completa

Detalles Bibliográficos
Autores principales: Al, Pepijn, Brehaut, Jamie, Weijer, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557161/
https://www.ncbi.nlm.nih.gov/pubmed/37803391
http://dx.doi.org/10.1186/s13063-023-07693-3
_version_ 1785117026525642752
author Al, Pepijn
Brehaut, Jamie
Weijer, Charles
author_facet Al, Pepijn
Brehaut, Jamie
Weijer, Charles
author_sort Al, Pepijn
collection PubMed
description Jon Merz raises two objections to our article on the ethics of behavioral influences in trial recruitment. In this response, we defend our article against these objections. We argue that Merz’s critique rests on a misunderstanding of our article, defend the daily life standard as a guardrail for leveraging cognitive biases, and argue that rejecting all behavioral influences is not a helpful nor a sustainable answer to their increasing use in trial recruitment.
format Online
Article
Text
id pubmed-10557161
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105571612023-10-07 Response to Merz Al, Pepijn Brehaut, Jamie Weijer, Charles Trials Letter Jon Merz raises two objections to our article on the ethics of behavioral influences in trial recruitment. In this response, we defend our article against these objections. We argue that Merz’s critique rests on a misunderstanding of our article, defend the daily life standard as a guardrail for leveraging cognitive biases, and argue that rejecting all behavioral influences is not a helpful nor a sustainable answer to their increasing use in trial recruitment. BioMed Central 2023-10-06 /pmc/articles/PMC10557161/ /pubmed/37803391 http://dx.doi.org/10.1186/s13063-023-07693-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter
Al, Pepijn
Brehaut, Jamie
Weijer, Charles
Response to Merz
title Response to Merz
title_full Response to Merz
title_fullStr Response to Merz
title_full_unstemmed Response to Merz
title_short Response to Merz
title_sort response to merz
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557161/
https://www.ncbi.nlm.nih.gov/pubmed/37803391
http://dx.doi.org/10.1186/s13063-023-07693-3
work_keys_str_mv AT alpepijn responsetomerz
AT brehautjamie responsetomerz
AT weijercharles responsetomerz

Ejemplares similares